Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma-Reference-Cited by-同舟云学术

Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma

Published:2022-08-29 Issue:1 Volume:89 Page:316-329
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Cheng Yiming¹^ORCID,Xue Yongjun²,Chen Lu¹,Masin Mark³,Maciag Paulo⁴,Peluso Teresa³,Zhou Simon¹,Li Yan¹

Affiliation:

1. Clinical Pharmacology & Pharmacometrics Bristol Myers Squibb Princeton NJ USA

2. Non‐Clinical Research & Development Bristol Myers Squibb Princeton NJ USA

3. Global Drug Development, Celgene International Sàrl a Bristol‐Myers Squibb Company Boudry Switzerland

4. Global Drug Development Bristol Myers Squibb Princeton NJ USA

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15498

Reference20 articles.

1. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos

2. Developing next generation immunomodulatory drugs and their combinations in multiple myeloma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetics and Absolute Oral Bioavailability of Lasalocid after Single Intravenous and Intracrop Administration in Laying Hens;Journal of Agricultural and Food Chemistry;2024-06-03

2. Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-06

3. A Phase I, Open-Label, Mass Balance Study of [14C]-Iberdomide in Healthy Subjects;European Journal of Drug Metabolism and Pharmacokinetics;2024-03-23

4. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group;The Lancet Oncology;2023-07

5. Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide;Clinical Pharmacology in Drug Development;2023-04-20